Home / Transcripts / Evaxion A/S (EVAX) · November 19, 2026

Evaxion A/S (EVAX) Earnings Call Transcript

November 19, 2026

NASDAQ US Health Care Biotechnology earnings 42 min

Earnings Call Speaker Segments

Helen Tayton-Martin executive
#1

Good morning, everyone, and thanks for joining Evaxion's Q3 Strategy and Business Update. I'm Helen Tayton-Martin, the company's Chief Executive Officer. Joining me on this call are Birgitte Rønø, our Chief Scientific Officer and Chief Operating Officer; Thomas Schmidt, Chief Financial Officer; and Mads Kronborg, who leads Investor Relations and Communications. Here's what we'll cover today: first, I'll explain how we are refocusing the strategy to generate the greatest possible value; after that, Birgitte will take you through what happened in R&D this quarter, including key data and progress involving our AI-Immunology platform, which is what underpins this strategic shift. Thomas is going to walk you through the quarter's financial results, and after that we'll close with some concluding remarks and then take your questions. Just a reminder that forward-looking statements may be made on today's call, and with that in mind, I'd point you to the statements in our most recent filings. Moving to the first agenda item, our strategy update: to put it very simply, Evaxion is now directing all of its own resources toward applying our AI-Immunology platform to our oncology portfolio. Moderna recently released phase III data that was groundbreaking and confirmed personalized cancer vaccines can genuinely produce meaningful clinical benefit in adjuvant melanoma. Because of that, over the past few weeks we've been proud and excited to present our own phase II three-year clinical results. In that study we treated patients with metastatic melanoma, using our AI-Immunology platform to predict high-quality, relevant antigens for each patient. Those predictions correlated with high precision in the immune response that was generated and, even more importantly, with deep and durable outcomes, as Birgitte will discuss later. Beyond that, we've been able to apply AI-Immunology to probe more deeply into the dark genome and find other antigen types, particularly endogenous retroviral elements, or ERVs. There we can pinpoint unique, highly conserved antigen sets that make an off-the-shelf vaccine approach possible, alongside the personalized neoantigen vaccines. We see a huge chance for Evaxion's AI-Immunology platform to spot and create cancer vaccines—both personalized and off-the-shelf—across many indications, tailored by antigen source and scope, and that's where Evaxion's greatest value sits. So moving forward, our own resources will concentrate on the three key areas at the bottom of this slide. First, advancing our two off-the-shelf cancer vaccines into the clinic: EVX-04 in AML and EVX-05 in GBM, with the latter done alongside Duke University. Second, we'll explore expanding EVX-01's potential past advanced melanoma, and in all likelihood we expect to pursue that via partnership. Third, we intend to keep finding additional antigens and indications by examining the dark genome more deeply using AI-Immunology; regarding the pipeline ahead, as noted a moment ago, we will move forward solely with our oncology assets. In addition, we believe we have generated substantial value through the preclinical assets and capabilities established in infectious disease over several years, among them EVX-B1 for Staph aureus, EVX-B2 for gonorrhea, EVX-B4 for Group A Streptococcus, and EVX-V1 for CMV. We'll continue looking for partners for those assets, and we'll work with partners only on other infectious disease programs when a partner comes forward; in autoimmune disease, we're putting the concepts we identified for tolerogenic vaccines and autoantibody binders to the test via AI-Immunology, and we'll complete that effort to validate the approach for potential partnering. As for what we accomplished during the last quarter, business development has been extremely busy, and we're continuing to move several conversations forward in parallel, each of them leveraging the recent data and validation of AI-Immunology with EVX-01 as well as the future off-the-shelf potential of EVX-04 and EVX-05, and more broadly across other indications, other cancer indications. Regarding research and development, a large portion of the most recent three-year data for EVX-01 was shared at ESMO and SITC, which Birgitte will discuss, and next month at ASH we'll provide another update on the EVX-04 program; our initial work with the EVX-B4 Group A Strep program has been completed, and we started early concept testing for the targets we identified in autoimmune disease; on the platform front, we felt genuinely honored that AI-Immunology received international recognition at the International Prix Galien Awards, winning the Best Digital Health Solution prize, which in our view provides additional validation that the Evaxion AI platform delivers meaningful clinical benefit. Finally, we've maintained strict discipline over our financial resources, directing them toward the highest-value opportunities, and we've prudently used our ATM to push the runway out to late 2027. As for our 2026 milestones, every one has now been met except for filing the EVX-04 clinical trial application. That filing is still on schedule to happen by year-end, in line with our refocused strategy around our IO programs and capabilities. With that, I'll turn things over to Birgitte, who will take us through the key R&D and AI-Immunology updates.

Birgitte Rønø executive
#2

Appreciate it, Helen. Just to build on what Helen described, oncology sits at the heart of our strategy — we're leaning on the clinical and translational data from EVX-01, our personalized cancer vaccine, along with the broader strengths of AI-Immunology, our proprietary AI platform, which helps us identify cancer antigens that matter clinically and then design vaccines around them. As mentioned, our priorities are getting EVX-04 and EVX-05, our off-the-shelf cancer vaccines, moving into clinical development; broadening EVX-01's reach into additional indications via partnerships; and continuing to explore the dark genome in search of cancer vaccine antigens. In the scientific update that follows, we'll walk through the evidence behind this focus and explain how the capabilities of our AI platform get translated into oncology product opportunities. I'd like to start with why personalized cancer vaccines make sense. Neoantigens are the target of personalized cancer vaccines. These are sequences that come from mutations specific to cancer, present only in the tumor and not in normal tissue, and that makes them very appealing as therapeutic targets. The difficulty lies in figuring out which of a patient's neoantigens will trigger an immune response that targets the tumor. AI-Immunology picks the most promising neoantigens by modeling each step, from cancer-specific mutations through expression, translation, presentation on the MHC molecules, and T-cell recognition. The AI-Immunology platform operates inside a larger patient-to-vaccine workflow. For every patient, tumor and blood samples are gathered and go through DNA and RNA sequencing. AI-Immunology then uses that information to predict, within 24 hours, the neoantigens specific to the patient, which guides the design of the personalized EVX-01 vaccine. Once manufactured, the vaccine is given together with checkpoint inhibitors. The whole process, from taking a biopsy to giving the vaccine, takes roughly seven weeks. In our phase II trial of EVX-01, we reported 89% accuracy when predicting immunogenic neoantigens. Now I'll move on to the clinical findings and the immune response data supporting that record-high accuracy; in our phase II EVX-01 study involving advanced melanoma, the two-year data demonstrated a 75% objective response rate and a 25% complete response. We also observed better responses compared with the week 12 assessment made after EVX-01 immunization began. Among 13 patients, seven who had stable disease or a partial response following 12 weeks of anti-PD-1 therapy showed an improved response, which corresponds to 54% after EVX-01 was administered. One other thing worth noting: adverse events tied to EVX-01 stayed within grade 1 and grade 2. With the one-year extension, we got longer follow-up in a smaller patient group, and among all six patients who took part in that extension on EVX-01 monotherapy, the clinical responses persisted through the end of the trial. Taken together, these clinical results are quite encouraging, showing clinical benefit for EVX-01 when given alongside anti-PD-1 therapy in advanced melanoma. Now on immunogenicity: EVX-01 produces strong vaccine-specific T-cell responses targeting the vaccine neoantigens. What matters most here is that the platform is able to identify antigens that the immune system recognizes. The T-cell responses specific to the vaccine that EVX-01 induced stay sustained across the whole three-year period, even when anti-PD-1 therapy is absent — and that therapy is given, or was given, solely in the first two years. As we mentioned, we hit 89% vaccine target precision, a record high. That makes clear just how accurately our AI-Immunology platform predicts. On top of that, 86% of the neoantigen responses we evaluated were de novo, so they arose newly instead of having existed beforehand. This is important since new T-cells generated through therapy have been connected to clinical benefit. Now let us examine more closely the phenotype of those T-cell responses, and how the magnitude of T-cell responses that EVX-01 induced ties back to the AI predictions. To start with, EVX-01 generates T-cell responses that are antigen-specific in both CD4+ and CD8+ cells. A CD4+ response was demonstrable in each patient we assessed, and CD8+ responses were additionally detectable in nine out of the 15 patients; sample analysis from the study is ongoing, so stay tuned. Additional immune and biomarker data are going to be shared over the next year. Next, we were able to demonstrate a positive correlation linking the AI prediction score given to these single neoantigens with the magnitude of the immune response that was observed. A stronger immune response was likewise linked to a higher prediction score. This represents a significant connection between what the platform predicts and the biological responses measured in patients. Building on that clinical and translational groundwork, I want to turn to the wider uses of AI-Immunology. The larger prospect involves deploying AI-Immunology across various antigen sources, cancer indications, and vaccine strategies. This platform takes in complicated patient data—genomic, transcriptomic, and proteomic—in order to find and rank cancer antigens. As this slide shows, our efforts cover neoantigens along with endogenous retrovirus, or ERVs, drawn from the dark genome, and we're currently examining further dark genome antigens. So that gives us two vaccine strategies that work together. First, personalized vaccines, which are made for one specific patient and go after private antigens — EVX-01 in melanoma is the example there. Second, off-the-shelf vaccines, which are designed for a broader patient group and target conserved ERV antigens, like EVX-04 for acute myeloid leukemia and EVX-05 for GBM. The additional indications you see on this slide — head and neck, lung, ovarian, bladder, colon, esophageal, testicular, and stomach cancers — show how wide the potential application could be, drawing on deep data mining and antigen profiling of patients. The strategic takeaway here is that this platform isn't limited to a single cancer type or a single vaccine approach. It gives us a foundation for going after opportunities in both personalized and off-the-shelf cancer vaccines. Now let's turn to what sets AI-Immunology apart. We discover broadly across many antigens and sources, with high target precision, and that opens up strategic product opportunities in both personalized and off-the-shelf cancer vaccines, reaching more patients and more cancer types. As noted, AI-Immunology investigates neoantigens derived from somatic mutations specific to cancer, ERV antigens arising from viral sequences integrated into the genome, and further dark genome antigens that are currently in development. That gives us a wider antigen repertoire. With the record-high target precision we've shown in clinical trials — the 89% vaccine target precision rate in the EVX-01 phase II trial being a prime example — we're well-positioned to identify the right targets. AI-Immunology's core component is essential for identifying which T-cell epitopes are most important, and that's a big part of why our target precision rate is so high. Our core code functions independent of antigen type and provides a common foundation for creating high-precision cancer vaccines, whichever antigen is selected. A wide antigen repertoire and high target precision — these two differentiators of AI-Immunology — create strategic product opportunities. Broader antigen breadth considerably increases the chances of identifying effective targets across more patients and more cancer types. Target-level precision boosts the likelihood of clinical success, because it supports stronger clinical outcomes. Taken as a whole, this places AI-Immunology not just as a single-vaccine platform but as the foundation for a broader cancer vaccine portfolio, combining the opportunity to help more patients with the possibility of better clinical results. EVX-04 demonstrates in a concrete way how we convert this wider discovery capacity into an off-the-shelf cancer vaccine program. Starting from sequencing data obtained from AML patients, we pinpointed ERV tumor antigens. From 5 million ERV antigen fragments along with their corresponding MHC ligands, AI-Immunology selected the 16 best antigen fragment sets. Right now, several vaccine candidates have been designed and tested. The lead candidate is moving into GMP manufacturing. We're working through the last preclinical testing and validation of the chosen ERV antigens, along with the work needed to enable a clinical trial application, or CTA, which we expect to submit in the second half of this year. In short, AI-Immunology combines broad antigen discovery with high target precision. We can find cancer antigens from several sources—neoantigens, ERVs, and other dark genome antigen approaches in development—using the same core predictive technology across antigen sources. Taken together, what these capabilities allow us to do is spot appropriate targets across a larger patient pool and a wider range of cancers, which backs both personalized and off-the-shelf strategies and lays the groundwork for better clinical results. On that note, I'll turn it over to Thomas, who will walk through the financial results for Q3.

Thomas Schmidt executive
#3

Right, thank you, Birgitte, and a warm welcome from me as well to everybody joining the call. I'll walk you through the Q3 financial results, and then we move on to the financial highlights. As the key financial highlights for the quarter, we've now successfully pushed our cash runway further, out to the end of 2027. That builds on what we communicated earlier, when we talked about runway reaching into the second half of 2027. We achieved this primarily by using our ATM program, but also through our continued disciplined allocation of resources. Both the ATM and, of course, our ongoing disciplined resource allocation also support the refocused strategy we now have and the updated pipeline, as we've just heard and seen. For the full year, we remain on track to deliver in line with our financial plan. We still expect an unchanged annual cash burn of roughly $14 million, as we communicated previously as well. Our cash position has clearly improved over the course of the year and now also reflects that in the extended runway. Turning to the details of our profit and loss, the statement clearly shows a net loss of $3.5 million for the quarter, compared with a $4.6 million profit in the same quarter a year ago. The main reason sits in recognized revenue; we recorded no recognized revenue in Q3 this year, while last year we out-licensed our EVX-B3 program to Merck, or MSD as it's called in Europe. At the same time this year, though, we've brought our operating cost down versus last year, both in R&D thanks to fewer headcounts and certainly in G&A with lower capital market costs, while we've simultaneously directed more resources, and therefore costs, into BD, business development activities. Our financial income and expenses for the quarter now also reflect a more normalized financial operation for us, in which the financial expense and income relate to interest on our debt and interest income from our bank and cash position. That compares with last year, when we had high financial income from the debt-to-equity agreement we did with the European Investment Bank and, on the other side, financial expenses tied to remeasurement of our derivative liability. That derivative liability has come down significantly and no longer has any significant impact on our financial expenses and income. Moving to our balance sheet, the main items include, obviously, our cash position, which stood at $13.3 million at the end of September. That includes proceeds of $2.2 million from our ATM program, which we utilized and received in August 2026; we've received further ATM proceeds in October of another $800,000, though that isn't reflected in the cash position at the end of September, but it is included in our cash runway, which, as I mentioned earlier, has now been extended toward the end of 2027. Equity is at $8.1 million, and that has clearly been raised as well by the ATM sales during August, while the net loss for the period has obviously had an effect too. Finally, though it is November, it is also worth pointing out that we filed an amendment to the Form F-1, which ties back to 2025, that settled agreement with the European Investment Bank, and this new amendment now permits them to exercise their warrants. It matters to note that under this registration we are not selling any securities, and no proceeds from sales of ordinary shares will come to us. Naturally, though, back in 2025 we did receive and record a debt cancellation of $4.1 million in exchange for warrants; once these warrants are exercised, that will mean we may get as much as another $1.5 million when and if the European Investment Bank exercises them. With that, I wrap up the financials for the quarter and pass it back to Helen for a few closing remarks.

Helen Tayton-Martin executive
#4

Thanks, Thomas. To wrap up, I believe we've laid out today a strategy with a sharper focus aimed at getting the most value from our assets and capabilities in immuno-oncology, and we've explained both the reasoning behind that plan and the way we intend to carry it out. Specifically, we've noted ongoing confirmation of the distinctive capabilities Evaxion holds in AI-Immunology, and we've also discussed how that shapes and advances the individual programs. Business development stays a top priority for the organization, with several conversations running in parallel, and we've managed to push the runway out to the end of 2027, and all of this places Evaxion in a strong position as we wrap up our milestones at the end of 2026; with that, I think we'll end the call here. Thank you for listening, and we're ready to take questions.

Thomas Flaten analyst
#5

Appreciate you taking the questions. Helen, I'd like to pick up on how you opened your prepared remarks. You mentioned how excited the market got after the Merck and Moderna data at ESMO. When you look back at the pivot you're making, was the infectious disease side simply not drawing interest, or has the immuno-oncology side just been so overwhelmingly interesting that it's partly why you pivoted? Or was it purely a resource constraint that forced you to pick one rather than doing both?

Helen Tayton-Martin executive
#6

I'd say it's really the enormous enthusiasm we're encountering around our immuno-oncology capabilities and how broad they are — as Birgitte laid out so well — that there's simply a great deal more validation on our side, and plenty of opportunity. It isn't that we lack belief in the infectious disease assets and capabilities; it's really about where the momentum sits and where the most significant value lies in what Evaxion has built and can accomplish. That comes through very clearly to us, and very clearly from the conversations we're having externally. If we didn't see promise in the infectious disease assets already in our portfolio, we wouldn't still be discussing them with partners. We do think value exists there. What this really comes down to is putting our own existing resources where we're seeing substantial engagement and opportunity. I hope that addresses your question.

Thomas Flaten analyst
#7

Yeah, that's great. On the subject of partnerships, is there anything we might hear about soon regarding the infectious disease work we're doing together with Merck?

Helen Tayton-Martin executive
#8

Nothing I'm able to share at this point.

Thomas Flaten analyst
#9

All right. Just a single question for Birgitte. Have you folks examined — and maybe you’ve shown this before, and I’m sorry if that’s the case — how CD8+ response correlates with clinical response? Since you had broad-based CD4+, we can sort of dismiss that as a universal response, but what about CD8+ correlating with clinical response?

Helen Tayton-Martin executive
#10

I’ll have Birgitte handle that one.

Birgitte Rønø executive
#11

Yeah, no, that’s a really good question. For the small number of patients who aren’t responding to study therapy, we actually don’t have a strong immune dataset, since they are early progressors. I’d say the dataset we have available right now can’t fully answer that question.

Thomas Flaten analyst
#12

Understood. Thanks a lot. It's no problem at all. I appreciate your taking the questions.

Birgitte Rønø executive
#13

Thanks.

Michael Okunewitch analyst
#14

Hey, guys. Good morning. Michael Okunewitch here. I was hoping you might speak briefly about how EVX-01's expansion strategy would work, and whether this is a case where some smaller proof of concept or preclinical work would be needed before seeking partners, or whether the melanoma validation on its own is enough to support expansion in those partner discussions?

Helen Tayton-Martin executive
#15

That's a great question. What we believe—and the engagement we have certainly centers on—is the validation already observed in advanced melanoma, and I think that sets the Evaxion platform and its clinical data apart. What we've been able to emphasize, as Birgitte showed on the slides, is that we have already invested quite a bit of effort examining other indications that may be feasible using the EVX-01 approach on its own. Another thing that interests us and our partners is that we can move past neoantigens in a personalized context. So there could be indications in which combining personalized antigens with ERVs is workable, and that does not really alter how the vaccine is made and delivered; it therefore creates opportunity relative to where we stand today. We can take the existing clinical package, we can take AI-Immunology's capacity to derive neoantigens along with other antigens, and potentially advance rapidly into other initial settings, potentially phase II, in other indications. I think that is a genuine advantage given where we are right now; those are the kinds of issues and questions we are considering in terms of where the best opportunity lies and how to widen our scope. Again, there is plenty of opportunity. It comes down to working through the best fit, the best setting, the best antigens.

Michael Okunewitch analyst
#16

Thanks. So with that strategic refocusing, what effect does it have on your plans for the autoimmune platform? Do you still intend to build it out, considering it sits earlier in that value creation pipeline and probably needs fewer resources than clinical stage assets?

Helen Tayton-Martin executive
#17

Yeah. No, that's a really good question. We intend to finish it. Our goal has been to pinpoint the appropriate targets for concept testing in autoimmune disease. Clearly, we're exploring approaches to lowering immune inflammation across various settings, and that concept testing has moved along. We expect to wrap up the validation of that, the lab work to run some testing around those concepts. I believe we intend at minimum to finish that work to determine whether we can present a persuasive case for how we'd move those programs ahead, once again, possibly through partnerships. It doesn't need extra resources right now, and we intend to finish that work so that we can actually say more about the potential for AI-Immunology to deliver in the autoimmune space. That is ongoing. It won't be stopping at this moment.

Michael Okunewitch analyst
#18

Thanks. I have just one quick follow-up on that point, and then I’ll get back into the queue. When you think about the validation work required to have a package that’s partnerable, what does that really involve? Would it mean producing an IND-ready product candidate for a particular disease, or is it more in the area of target discovery? I’m trying to get a sense of how much validation is needed before you can take it to partners.

Helen Tayton-Martin executive
#19

That probably depends. I'll have Birgitte share her thoughts on where we stand and on the value of what we believe we can generate, but my sense is that basically we'll be early.

Birgitte Rønø executive
#20

Right. So at this point we’ve come up with two therapeutic concepts. The first one is a tolerogenic vaccine, and what it’s trying to do is re-educate the immune system so that it moves toward self-tolerance. The AI-Immunology team has worked on that concept, along with the bioinformaticians; in the lab, we’re gradually getting things ready to test a few of these concepts. And then there’s the second therapeutic approach, which rests on autoantibody binders, and the goal there is to bring down the levels of pathogenic autoantibodies. We’ve begun discussing these concepts and presenting them at various conferences, so our hope is that we’ll manage to generate at least some interest from potential partners early on, meaning even before we have a defined product candidate.

Helen Tayton-Martin executive
#21

So, it's really early proof of concept.

Birgitte Rønø executive
#22

Yes.

Michael Okunewitch analyst
#23

Okay. Thanks a lot. That added clarity is much appreciated.

Birgitte Rønø executive
#24

Thanks.

Charles Wallace analyst
#25

Hello, and thank you for taking my question. I'll start with this one. With the two positive phase III cancer vaccine readouts now in the field — INTerpath-001 in adjuvant melanoma, and then the REGAL study in transplant-ineligible AML just two days ago — I'm curious about your pipeline: where does the interest lie specifically? Is it more toward the personalized vaccine approach, or toward the off-the-shelf vaccine approach? That's my first question. Thank you.

Helen Tayton-Martin executive
#26

Alright. I'd certainly say both, as far as we're able to disclose anything at this stage. The broader potential across indications is clearly of interest, but an off-the-shelf vaccine plainly offers advantages — a simpler supply chain, simpler delivery, and a simpler ability to deliver a product — and that is obviously of considerable interest; at this point, though, it isn't clinically validated. There's a belief that the personalized vaccine approach can deliver clinically. We have demonstrated that, and others have demonstrated that. Off-the-shelf is very much of interest, and it really comes down to moving toward clinical validation. So I'd say, at the moment, interest is equal in both areas.

Charles Wallace analyst
#27

All right, that helps. Then I suppose, regarding the infectious disease programs — the out-license program EVX-B3 and the co-development program of EVX-B2 — can we take it that nothing has really changed in those two programs? Yes, that is my following question. Thank you.

Helen Tayton-Martin executive
#28

B3, of course, is out-licensed through a collaboration with MSD, and it is progressing. Any additional updates on that will really emerge from what MSD does. As for the B2 program, it is in collaboration with Afrigen and our RNA platform, and once again, work has carried on there. There will be data packages for B2, just as with B1 and B4, as well as B1, as I mentioned in my comments, that are available — that we have kept building on over the course of this year and are available, will be available, in those partnering conversations. So from a partner standpoint, B3 is advancing with MSD, and in due course we will be able to say more about that, but it is really driven by the next stages with them. And so, from our perspective, things have not shifted significantly at this point until we reach the next milestone with that one.

Charles Wallace analyst
#29

Great. Thanks for taking my questions.

Helen Tayton-Martin executive
#30

Okay, great.

Danya Ben-Hail analyst
#31

Hi. Thanks for taking our questions. As a follow-up to the earlier ones, could you say whether potential partners have any questions or diligence around EVX-01?

Helen Tayton-Martin executive
#32

Not really, though I can speak to the fact that they do ask all the questions, many questions that would come up in this setting as well, and it is really about understanding turnaround time, how deep the immune responses are that we see, the correlations there, the quality of the antigens and the scoring that we generate. They are really looking very closely, given that the whole world, the whole landscape around cancer vaccines has now shifted gears, and it is really important to understand key scientific differentiators and also platform delivery opportunities where maybe there is scope to reduce the timeframe, they look at the modality of delivery, et cetera. So all the sorts of things that come with drilling into how a product platform like this works; then thinking about that more broadly in terms of different indication contexts, which is very much what we are doing too.

Danya Ben-Hail analyst
#33

Uh-huh, thanks. On the manufacturing side, are you doing anything to shorten that vein-to-vein time from the 7 weeks you brought up?

Helen Tayton-Martin executive
#34

We're aware it's achievable. Birgitte, would you like to speak to what we know about that?

Birgitte Rønø executive
#35

Right. We've structured the supply chain in a decentralized way, which means we've been partnering with several different CDMOs. There's clearly a chance to bring all those many activities under a single roof so manufacturing time comes down. On top of that, there's been global shipping, moving from the clinical site to the sequencing facility and then shipping the drug product back to the clinical site. All of that adds up across the overall timelines. There are going to be multiple ways the turnaround time could be cut significantly.

Danya Ben-Hail analyst
#36

Great, thanks for that. One last question regarding EVX-04. When can we expect further details about the clinical trial design?

Birgitte Rønø executive
#37

As Helen Tayton-Martin said, we'll be presenting target validation data at ASH in December. We're also moving quickly toward a clinical trial application later this year. At that point, we should most likely be in a position to share additional details on the patient population and the trial design.

Danya Ben-Hail analyst
#38

Perfect. Thank you very much.

Helen Tayton-Martin executive
#39

Thank you.

Helen Tayton-Martin executive
#40

Thanks. I really appreciate everyone tuning in to today's strategy and business update for Q3. We're genuinely enthusiastic about where Evaxion is headed, and thank you for the questions. Thanks.

Operator operator
#41

Thanks, everyone — that brings us to the end of today's conference call. We appreciate you joining us. You're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Evaxion A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Evaxion A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.